Simultaneous

A simple and sensitive spectrophotometric method for the determination of albendazole and levamisole hydrochloride in pharmaceutical dosage forms has been developed. The absorption maxima were found at 295nm for albendazole and 213 nm for levamisole hydrochloride using ammonium dihydrogen phosphate: methanol as solvent. Beer's law was obeyed for both the drugs in the concentration range of 5-25 for albendazole with correlation coefficient 0.998 and 2-10 for levamisole hydrochloride with correlation coefficient 0.997. The limits of detection for albendazole and levamisole hydrochloride were found to be 0.305µg/mL and 0.732µg/mL respectively and the limits of quantitation were 0.924µg/mL and 2.2µg/mL respectively. Accuracy of the method verified by performing recovery using simultaneous equation method and found to be 98 to 99.5%w/w for albendazole and 97.97 to 99.55 %w/w for levamisole hydrochloride. %RSD of repeatability and intermediate precision studies were found to be

A simple, accurate, precise and reproducible method has been developed for the simultaneous estimation of Vildagliptin and Metformin hydrochloride in combined tablet dosage forms. As there are no reported UV methods for the simultaneous estimation of Vildagliptin and Metformin hydrochloride in their combined dosage form, a need was felt to develop new methods to analyze the drugs simultaneously. The estimation was done by multi-wavelength technique, at wavelengths of 217 nm and 234 nm over the concentration ranges of 0.7µg/ml and 7 µg/ml with mean recovery 100% for both drugs Vildagliptin and Metformin hydrochloride respectively. The results of the analysis were validated statistically and recovery studies were carried out as per ICH guide lines. Thus the proposed method can be successfully applied for the simultaneous estimation of Vildagliptin and Metformin hydrochloride in routine analysis work.

Present work describes a selective, precise and accurate Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method for simultaneous estimation of Escitalopram Oxalate (ESC) and Etizolam (ETI) on Kromasil 100 C18, 5µ(150×4.6 mm) Column using Acetonitrile:0.005 M Hexane Sulfonic Acid pH 3.0 (adjusted with o-phosphoric acid) (40:60 v/v) as mobile phase, at a flow rate of 1.0 ml/min and the detection wavelength was 254 nm. The retention time for ESC and ETI was found to be 3.66 and 8.07 min, respectively. The ion-pairing reagent improved the retention of polar ESC on Reverse-phase column. The method was validated for linearity, precision, accuracy, LOD, LOQ robustness, solution stability and specificity. The method was linear in the concentration range of 20-160µg/ml for ESC and 2-16 µg/ml for ETI with a correlation coefficient of 0.9994 and 0.9993 for respective drugs. The percent recovery was found in the range of 98.14-101.72% and 98.83-101.12 % for ESC and ETI, respectively. The specificity of method was established based on peak purity data. The proposed method was successfully applied for quantitative determination of escitalopram oxalate and Etizolam in combined tablet dosage form for routine analysis.